CAMBRIDGE, Mass.--(BUSINESS WIRE)--Be Biopharma, Inc. (“Be Bio”), a company pioneering the discovery and development of Engineered B Cell Medicines (BeCMs), will present preclinical research today ...
Gene editing platforms like CRISPR-Cas9 that rely on nuclease activity introduce effective modifications, however, they arise from double strand DNA breaks (DSBs) introduced by the nuclease that can ...
SAN DIEGO & PHILADELPHIA--(BUSINESS WIRE)--Capstan Therapeutics, Inc., a biotechnology company dedicated to developing and delivering precise in vivo cell engineering to patients, launched today with ...
Researchers at the Toyota Research Institute (TRI) in Los Altos, Calif. have released a pair of papers describing a technique for incorporating precise engineering constraints into a generative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results